Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) — Financial Flexibility Index
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a Financial Flexibility Index of -0.03x as of June 2026. Free cash flow of $-244.60K (operating CF $-244.61K minus capex $3.00) represents 0% of total liabilities ($9.14 Million). Check how aggressively does Drugs Made In America Acquisition Corp. reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Drugs Made In America Acquisition Corp. Ordinary Shares Financial Flexibility Index (2024–2025)
Historical Financial Flexibility Index trend for Drugs Made In America Acquisition Corp. Ordinary Shares across 2 annual periods. For the full cash flow conversion analysis, see Drugs Made In America Acquisition Corp. cash flow conversion.
Annual Financial Flexibility Index for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2025)
Year-by-year free cash flow to debt coverage for Drugs Made In America Acquisition Corp. Ordinary Shares. Explore DMAA debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.07x | $-539.19K | $-539.19K | $7.28 Million | ▲ +100.0% |
| 2024 | -216.50x | $-172.26K | $-172.26K | $795.67 | — |